{
  "id": "41103278",
  "source": "MED",
  "pmid": "41103278",
  "pmcid": "PMC12523554",
  "fullTextIdList": {
    "fullTextId": [
      "PMC12523554"
    ]
  },
  "doi": "10.2147/jir.s554898",
  "title": "Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect.",
  "authorString": "Gu L, Lin J, Yue J, Liu Z, Huang JA.",
  "authorList": {
    "author": [
      {
        "fullName": "Gu L",
        "firstName": "Lei",
        "lastName": "Gu",
        "initials": "L",
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China."
            }
          ]
        }
      },
      {
        "fullName": "Lin J",
        "firstName": "Jing",
        "lastName": "Lin",
        "initials": "J",
        "authorId": {
          "type": "ORCID",
          "value": "0000-0002-6368-6455"
        },
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China."
            }
          ]
        }
      },
      {
        "fullName": "Yue J",
        "firstName": "Jian",
        "lastName": "Yue",
        "initials": "J",
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "The People's Hospital of Gaozhou, Gaozhou, Guangdong, People's Republic of China."
            }
          ]
        }
      },
      {
        "fullName": "Liu Z",
        "firstName": "Zeyi",
        "lastName": "Liu",
        "initials": "Z",
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China."
            }
          ]
        }
      },
      {
        "fullName": "Huang JA",
        "firstName": "Jian-An",
        "lastName": "Huang",
        "initials": "JA",
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China."
            }
          ]
        }
      }
    ]
  },
  "authorIdList": {
    "authorId": [
      {
        "type": "ORCID",
        "value": "0000-0002-6368-6455"
      }
    ]
  },
  "dataLinksTagsList": {
    "dataLinkstag": [
      "altmetrics"
    ]
  },
  "journalInfo": {
    "volume": "18",
    "journalIssueId": 3884200,
    "dateOfPublication": "2025 ",
    "monthOfPublication": 0,
    "yearOfPublication": 2025,
    "printPublicationDate": "2025-01-01",
    "journal": {
      "title": "Journal of inflammation research",
      "medlineAbbreviation": "J Inflamm Res",
      "issn": "1178-7031",
      "isoabbreviation": "J Inflamm Res",
      "essn": "1178-7031",
      "nlmid": "101512684"
    }
  },
  "pubYear": "2025",
  "pageInfo": "14171-14173",
  "abstractText": "Janus kinase (JAK) inhibitors, developed for autoimmune diseases, have been repurposed as potential therapies for severe COVID-19. Growing evidence indicates that their clinical utility is heterogeneous and cannot be generalized as a class effect. In this Perspective, we focus on the clinical evidence base for JAK inhibitors in COVID-19 and emphasize baricitinib as the the only agent with consistent mortality benefit and highlights the need for agent-specific recommendations and individualized treatment strategies.",
  "affiliation": "Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.",
  "publicationStatus": "epublish",
  "language": "eng",
  "pubModel": "Electronic-eCollection",
  "pubTypeList": {
    "pubType": [
      "discussion",
      "Journal Article"
    ]
  },
  "keywordList": {
    "keyword": [
      "Immunomodulation",
      "Ruxolitinib",
      "Janus Kinase Inhibitors",
      "Tofacitinib",
      "Baricitinib",
      "Covid-19"
    ]
  },
  "fullTextUrlList": {
    "fullTextUrl": [
      {
        "availability": "Subscription required",
        "availabilityCode": "S",
        "documentStyle": "doi",
        "site": "DOI",
        "url": "https://doi.org/10.2147/JIR.S554898"
      },
      {
        "availability": "Open access",
        "availabilityCode": "OA",
        "documentStyle": "html",
        "site": "Europe_PMC",
        "url": "https://europepmc.org/articles/PMC12523554"
      },
      {
        "availability": "Open access",
        "availabilityCode": "OA",
        "documentStyle": "pdf",
        "site": "Europe_PMC",
        "url": "https://europepmc.org/articles/PMC12523554?pdf=render"
      }
    ]
  },
  "isOpenAccess": "Y",
  "inEPMC": "Y",
  "inPMC": "Y",
  "hasPDF": "Y",
  "hasBook": "N",
  "hasSuppl": "N",
  "citedByCount": 0,
  "hasData": "N",
  "hasReferences": "Y",
  "hasTextMinedTerms": "Y",
  "hasDbCrossReferences": "N",
  "hasLabsLinks": "Y",
  "license": "cc by-nc",
  "hasEvaluations": "N",
  "authMan": "N",
  "epmcAuthMan": "N",
  "nihAuthMan": "N",
  "hasTMAccessionNumbers": "N",
  "dateOfCompletion": "2025-10-17",
  "dateOfCreation": "2025-10-17",
  "firstIndexDate": "2025-10-17",
  "fullTextReceivedDate": "2025-10-21",
  "dateOfRevision": "2025-10-19",
  "electronicPublicationDate": "2025-10-11",
  "firstPublicationDate": "2025-10-11"
}